NovMetaPharma and the FSHD Canada Foundation Establish Collaboration to Advance Cyclo-Z, a First-in-Class Oral Muscle-Preserving Therapy, into Facioscapulohumeral Muscular Dystrophy

Disease-foundation-funded program extends NovMetaPharma’s muscle-preservation platform into a serious neuromuscular disease with no approved disease-modifying treatment; collaboration provides non-dilutive capital to support clinical development SEOUL, South Korea, July 06, 2026 (GLOBE NEWSWIRE) — NovMetaPharma Co., Ltd. (“NovMetaPharma” or “NMP”), a clinical-stage biopharmaceutical company that develops first-in-class drugs with differentiated mechanisms for metabolic disease, today announced […]